Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intellia Therapeutics (Nasdaq: NTLA) announced inducement equity awards granted on February 1, 2026 under its 2024 Inducement Plan.
The company awarded time-based restricted stock units totaling 30,600 shares to six new employees, vesting one-third annually over three years, subject to continued service. Awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – NTLA
On Feb 6, the day this news came out, NTLA closed 10.73% above the previous close.
Data tracked by StockTitan Argus for the Feb 6 session.
Key Figures
- Pre-news price change
- -10.28%
- Change over prior 24 hours before this announcement
- Inducement RSUs granted
- 30,600 shares
- Time-based RSUs granted to new employees on Feb 1, 2026
- Employees receiving grants
- 6 employees
- New hires awarded inducement RSUs under 2024 Inducement Plan
- Vesting schedule
- One-third annually over 3 years
- RSU vesting conditioned on continued service
- Nasdaq rule cited
- Rule 5635(c)(4)
- Inducement grants made in reliance on this listing rule
- Inducement Plan year
- 2024 Inducement Plan
- Plan adopted by board in June 2024
Historical Context
-
FDA removed clinical hold on MAGNITUDE-2 Phase 3 ATTRv-PN trial.
-
Planned presentation at J.P. Morgan Healthcare Conference with webcast access.
-
RSU inducement grants to two new employees under 2024 Inducement Plan.
-
RSU inducement awards to three new employees under Nasdaq Rule 5635(c)(4).
-
Longer-term Phase 1 data for nexiguran ziclumeran in ATTR-CM patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
rsus financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
vest financial
crispr-based therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 30,600 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.